If you live with a persistent ache, the internet has already found you. Somewhere between the adverts and the wellness reels sits a treatment your GP has never mentioned, described in language that sounds clinical without quite being medical.
A person reading health information on a laptop at a kitchen table with a mug
Some of it is legitimate care that simply has not reached the NHS pathway yet. Some of it is a long way from proven. Peptide therapy is a useful example, because it sits squarely in that grey area. American clinics including Core Medical & Wellness peptide therapy list compounds such as BPC-157 and TB-500 for chronic pain and tissue repair.
Neither is a licensed medicine in the UK. That does not automatically make it worthless, but it does change what you are agreeing to.
Why Do New Treatments Reach You Before Your GP?
Because the routes are different lengths.
A treatment becomes standard NHS care only after trials, regulatory approval and guidance. That process routinely takes 10 years or more from first study to routine use, and it is designed to be slow. A private clinic can offer something considerably sooner, and a social platform can advertise it sooner still.
Chronic pain is the term for pain lasting beyond 3 months, and it affects a large share of UK adults. That combination, a common problem and a slow pipeline, is exactly the gap the marketing fills.
So the order you encounter things in is almost reversed. You meet the newest options first, described by whoever is selling them, and the cautious summary arrives last if at all.
What Does Licensed Actually Mean?
In the UK, a medicine needs a marketing authorisation from the Medicines and Healthcare products Regulatory Agency before it can be sold as a treatment. That authorisation says a regulator has reviewed evidence of quality, safety and effectiveness for a stated purpose.
Several things are commonly mistaken for it:
- Sold legally somewhere else, which reflects that country’s rules rather than a safety verdict.
- Available to buy online, which reflects enforcement gaps rather than approval.
- Used in research, which means it is being tested, not that it passed.
- Prescribed off-label, which is a licensed medicine used outside its approved indication by a clinician taking responsibility.
That last one is genuinely different from an unlicensed compound, and clinics sometimes blur the two. It is a fair question to ask directly.
Where Do Peptides Sit Right Now?
Honestly, in the early column.
Pharmacy shelves lined with boxed medicines and a pharmacist in the background
Peptides are short chains of amino acids, and the body uses them for signalling. That is real biology, and it is why the idea is plausible rather than absurd. Plausible is not the same as demonstrated.
A preclinical study is one done in a laboratory or in animals, before human testing begins. For BPC-157 and TB-500 specifically, most published work is still at that stage rather than in large human trials. Neither holds a UK marketing authorisation.
In 2023 the United States Food and Drug Administration placed BPC-157 in the category of substances raising safety concerns for pharmacy compounding. That is not a ban, and it is a signal worth weighing.
Both are also prohibited in competitive sport under anti-doping rules. If you compete at any level with testing, that alone settles the question.
None of this means clinics offering them are acting in bad faith. It means the evidence is thinner than the marketing language usually suggests, and you are the one carrying that risk.
How Do You Read a Clinic’s Claims?
A few patterns are reliable tells.
Watch for mechanism described as though it were outcome. A page explaining how something promotes angiogenesis or modulates inflammation is describing a theory of action, not proof that patients got better.
Watch for the absence of numbers. Genuine evidence comes with sample sizes, comparison groups and effect sizes. Marketing comes with adjectives.
Watch for testimonials doing the heavy lifting, and for any claim that a single treatment addresses a long list of unrelated conditions.
Which Questions Are Worth Asking?
Take these to any consultation, private or NHS:
- Is this licensed in the UK for what you are proposing to treat?
- If not, is it unlicensed or being used off-label, and who carries clinical responsibility?
- What human evidence exists, and can I see it?
- What are the known side effects, and what is not yet known?
- What happens if it does not work, and what is the total cost?
- Would you still recommend it if I could not pay privately?
A clinician comfortable with their offer will answer all 6 without defensiveness. Hesitation on the first 2 is informative.
Tell your GP either way. Unlicensed compounds can interact with prescribed medicines, and your record should reflect what you are actually taking.
Frequently Asked Questions About Newer Treatments
Is Unlicensed the Same as Illegal?
No. Unlicensed means no marketing authorisation for that use. Supply and prescribing are governed by separate rules, which is why the position can look confusing from outside.
Does Private Care Mean Better Care?
It means faster access and more choice. Speed and quality are different things, and paying for something is not evidence that it works.
Should You Try It If Nothing Else Has Helped?
That is a reasonable position to hold, and it deserves an honest conversation rather than a hopeful one. Persistent pain is exhausting, and exhaustion makes optimistic claims harder to weigh.
Where Can You Get Balanced Information?
Charities and professional bodies are a better starting point than a clinic’s own pages. The British Pain Society and Pain Concern both publish material aimed at patients rather than buyers.
Deciding Without Guessing
None of this argues for doing nothing. Living with untreated pain has real costs, and the unglamorous things still matter. Sleep, movement and the sort of living clean and being healthy habits that rarely get advertised do more than most paid interventions. Even a roll-on wellbeing kit earns its place if it helps you wind down at night.
What it argues for is knowing which of the 3 columns a treatment sits in before you pay. Licensed, off-label, or unlicensed and early.
Ask the question plainly, and judge the answer by how readily it comes. A clinic that tells you exactly where its offer sits is one you can make a real decision about.
**This is a collaborative post
